Enzene Biosciences Hit by Cyberattack on U.S. Ops

Enzene Biosciences, a biotechnology subsidiary of Indian pharmaceutical giant Alkem Laboratories, has experienced a cybersecurity breach that disrupted its U.S. operations, according to a report by The Cyber Express. The incident, which involved unauthorized access, reportedly led to a compromise of company funds, although the scope and financial impact have not been disclosed.

The attack underscores the growing threat facing the biotech and pharmaceutical sectors, which continue to be high-value targets due to their proprietary research and financial assets. Enzene, which operates globally under the umbrella of Alkem Laboratories, has not released a public statement detailing the nature of the breach or the response measures underway.

Cyberattacks on healthcare-related firms have surged in recent years, often resulting in operational disruptions and financial losses. The incident involving Enzene highlights the importance of bolstering cybersecurity frameworks as organizations expand internationally and increase their digital footprints in critical markets like the United States.